The Patent Finder

Centro de Inmunologia Molecular

14 patents currently held · Updated Nov 21, 2026
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 7 name spellings.

2
Ending by 2030
Apr 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 8, 2027
    The maintenance fee for Antibodies with Increased Affinity for the Epidermal Growth Factor Receptor and Fragments Derived Therefrom (US 11,718,676) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
  • 1 fee due Mar 26, 2027
    The maintenance fee for Ganglioside GM3-CONTAINING Nanoparticles as Immunomodulators (US 11,766,462) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
  • 1 fee due Apr 29, 2027
    The maintenance fee for Method for obtaining high-yield, stable expression cell clones and antibody molecules obtained thereby (US 10,457,747) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
  • 1 fee due May 7, 2027
    The maintenance fee for Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines (US 11,806,396) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
  • 1 fee due Jun 8, 2027
    The maintenance fee for IL-2 derivative polypeptides (US 9,206,243) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
  • 1 fee due Sep 12, 2027
    The maintenance fee for Fusion proteins composed of an interleukin-2 mutein and type I interferon (US 11,926,654) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,435,521Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukaemia
In force
 · USPTO record
In forceUSPTO record
US 8,470,322Anti sulfatides and anti sufated proteoglycans antibodies and their use
In force
 · USPTO record
In forceUSPTO record
US 9,206,243IL-2 derivative polypeptides
In force
 · USPTO record
In forceUSPTO record
US 9,790,279Pharmaceutical compositions for the treatment of tumors expressing EGFR and GM3 N-glycolyl ganglioside (NeuGcGM3)
In force
 · USPTO record
In forceUSPTO record
US 10,457,747Method for obtaining high-yield, stable expression cell clones and antibody molecules obtained thereby
In force
 · USPTO record
In forceUSPTO record
US 12,019,073Method for the Treatment of Patients with Carcinomas
In force
 · High confidence
In forceHigh confidence
US 12,280,109Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
In force
 · USPTO record
In forceUSPTO record
US 11,806,396Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
In force
 · USPTO record
In forceUSPTO record
US 11,718,676Antibodies with Increased Affinity for the Epidermal Growth Factor Receptor and Fragments Derived Therefrom
In force
 · High confidence
In forceHigh confidence
US 11,766,462Ganglioside GM3-CONTAINING Nanoparticles as Immunomodulators
In force
 · High confidence
In forceHigh confidence
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 8 patents in force now held by others · 11 lapsed for an unpaid fee · 14 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 5 abandoned · 11 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited